Treatment of Benzodiazepine Dependence
The DOI matches its Crossref record; 65 of the 66 references it cites were found in a registry or an index.
Abstract
Long-term use of benzodiazepines can lead to dependence. Symptoms of withdrawal include anxiety, irritability, confusion, seizures, and sleep disorders. Withdrawal management relies on the use of a single agent (diazepam) and gradual dose reduction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, use of these medications is associated with an increased risk of adverse events, including falls, motor vehicle accidents, cognitive impairment, delirium, overdose, and death, particularly when BZDs are used in combination with central nervous system (CNS) depressants such as alcohol or opioids.1–3”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [2]
In the citing paper
“Patients can experience life-threatening withdrawal symptoms with abrupt or rapid discontinuation of BZDs, and some patients experience significant symptoms even with gradual dose reduction.2,20,68”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [2]
In the citing paper
“Most existing guidance recommend a flexible approach to tapering, reducing the dose at a rate dictated by each patient’s ability to tolerate withdrawal symptoms and allowing the process to take as long as patients need.2,59,69,79,80,100–102”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [2]
In the citing paper
“Sleep disturbance is a common symptom during BZD tapering and may contribute to symptom exacerbation of underlying mood or psychotic disorders.2,164,165”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [2]
In the citing paper
“BZD tapering may exacerbate or cause recurrence of psychiatric symptoms that may warrant more intensive clinical oversight.2,150”
From Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025) · cites this paper as [2]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders, 5th ed.
Carter, M. J. (2014) · Therapeutic Recreation Journal · Cited by 15,169
The Transtheoretical Model of Health Behavior Change.
Prochaska, J. O., & Velicer, W. F. (1997) · American Journal of Health Promotion · doi:10.4278/0890-1171-12.1.38 · Cited by 7,782
(2013) · Cited by 2,393
Sequence and functional expression of the GABAA receptor shows a ligand-gated receptor super-family
Schofield, P. R., Darlison, M. G., Fujita, N., Burt, D. R., Stephenson, F. A., Rodriguez, H., Rhee, L. M., Ramachandran, J., Reale, V., Glencorse, T. A., et al. (1987) · Nature · doi:10.1038/328221a0 · Cited by 1,622
A Meta-Analytic Review of Psychosocial Interventions for Substance Use Disorders
Dutra, L., Stathopoulou, G., Basden, S. L., Leyro, T. M., Powers, M. B., & Otto, M. W. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111851 · Cited by 1,287
Drugs of Abuse and Stress Trigger a Common Synaptic Adaptation in Dopamine Neurons
Saal, D., Dong, Y., Bonci, A., & Malenka, R. C. (2003) · Neuron · doi:10.1016/s0896-6273(03)00021-7 · Cited by 1,147
Nonpharmacological interventions for insomnia: a meta-analysis of treatment efficacy
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.8.1172 · Cited by 1,098
Benzodiazepine Use in the United States
Olfson, M., King, M., & Schoenbaum, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1763 · Cited by 786
Polydrug abuse: a review of opioid and benzodiazepine combination use
Jones, J. D., Mogali, S., & Comer, S. D. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.07.004 · Cited by 703
Benzodiazepines revisited—will we ever learn?
Lader, M. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03563.x · Cited by 573
Increasing Benzodiazepine Prescriptions and Overdose Mortality in the United States, 1996–2013
Bachhuber, M. A., Hennessy, S., Cunningham, C. O., & Starrels, J. L. (2016) · American Journal of Public Health · doi:10.2105/ajph.2016.303061 · Cited by 531
Neural bases for addictive properties of benzodiazepines
Tan, K. R., Brown, M., Labouèbe, G., Yvon, C., Creton, C., Fritschy, J.-M., Rudolph, U., & Lüscher, C. (2010) · Nature · doi:10.1038/nature08758 · Cited by 397
Pisani, M. A., Murphy, T. E., Araujo, K. L. B., Slattum, P., Van Ness, P. H., & Inouye, S. K. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e318192fcf9 · Cited by 361
Benzodiazepine harm: how can it be reduced?
Lader, M. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04418.x · Cited by 359
Withdrawal reactions from chlordiazepoxide (?Librium?)
Hollister, L. E., Motzenbecker, F. P., & Degan, R. O. (1961) · Psychopharmacologia · doi:10.1007/bf00429621 · Cited by 340
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
Withdrawing Benzodiazepines in Primary Care
Lader, M., Tylee, A., & Donoghue, J. (2009) · CNS Drugs · doi:10.2165/0023210-200923010-00002 · Cited by 318
Cognitive and sedative effects of benzodiazepine use
Buffett-Jerrott, S., & Stewart, S. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023396654 · Cited by 312
Huang, B., Dawson, D. A., Stinson, F. S., Hasin, D. S., Ruan, W. J., Saha, T. D., Smith, S. M., Goldstein, R. B., & Grant, B. F. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0708 · Cited by 306
Kurko, T. A. T., Saastamoinen, L. K., Tähkäpää, S., Tuulio-Henriksson, A., Taiminen, T., Tiihonen, J., Airaksinen, M. S., & Hietala, J. (2015) · European Psychiatry · doi:10.1016/j.eurpsy.2015.09.003 · Cited by 280
The Mechanistic Classification of Addictive Drugs
Lüscher, C., & Ungless, M. A. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030437 · Cited by 255
Benzodiazepines: Risks and Benefits. A Reconsideration
Baldwin, D. S., Aitchison, K., Bateson, A., Curran, H. V., Davies, S., Leonard, B., Nutt, D. J., Stephens, D. N., & Wilson, S. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113503509 · Cited by 249
Benzodiazepine Use and Hip Fractures in the Elderly: Who Is at Greatest Risk?
Wagner, A. K., Zhang, F., Soumerai, S. B., Walker, A. M., Gurwitz, J. H., Glynn, R. J., & Ross-Degnan, D. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.14.1567 · Cited by 241
Effectiveness of current treatment approaches for benzodiazepine discontinuation: a meta‐analysis
Parr, J. M., Kavanagh, D. J., Cahill, L., Mitchell, G., & Young, R. M. (2009) · Addiction · doi:10.1111/j.1360-0443.2008.02364.x · Cited by 212
Gustavsen, I., Bramness, J. G., Skurtveit, S., Engeland, A., Neutel, I., & Mørland, J. (2008) · Sleep Medicine · doi:10.1016/j.sleep.2007.11.011 · Cited by 201
The Relationship between Benzodiazepine Use and Traffic Accidents: A Systematic Literature Review
Smink, B. E., Egberts, A. C. G., Lusthof, K. J., Uges, D. R. A., & de Gier, J. J. (2010) · CNS Drugs · doi:10.2165/11533170-000000000-00000 · Cited by 174
Substanzkonsum und substanzbezogene Störungen in Deutschland im Jahr 2012
Pabst, A., Kraus, L., Matos, E. G. D., & Piontek, D. (2013) · SUCHT · doi:10.1024/0939-5911.a000275 · Cited by 173
Psychological treatment for insomnia in the regulation of long-term hypnotic drug use
Morgan, K., Dixon, S., Mathers, N., Thompson, J., & Tomeny, M. (2004) · Health Technology Assessment · doi:10.3310/hta8080 · Cited by 166
Voshaar, R. C. O., Gorgels, W. J. M. J., Mol, A. J. J., Van Balkom, A. J. L. M., Van De Lisdonk, E. H., Breteler, M. H. M., Van Den Hoogen, J. M., & Zitman, F. G. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.6.498 · Cited by 154
The Epidemiology of Long-Term Benzodiazepine Use
Neutel, C. I. (2005) · International Review of Psychiatry · doi:10.1080/09540260500071863 · Cited by 148
The Benzodiazepine–Dementia Disorders Link: Current State of Knowledge
Pariente, A., de Gage, S. B., Moore, N. D., & Bégaud, B. (2015) · CNS Drugs · doi:10.1007/s40263-015-0305-4 · Cited by 144
Petitjean, S., Ladewig, D., Meier, C. R., Amrein, R., & Wiesbeck, G. A. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e328105e0f2 · Cited by 132
Mugunthan, K., McGuire, T., & Glasziou, P. (2011) · British Journal of General Practice · doi:10.3399/bjgp11x593857 · Cited by 123
Treating Alcohol and Drug Abuse: An Evidence Based Review
(2003) · Wiley eBooks · doi:10.1002/3527601465 · Cited by 117
Benzodiazepines: More Behavioural Addiction than Dependence
de las Cuevas, C., Sanz, E., & de la Fuente, J. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1376-8 · Cited by 113
In Vivo Measurement of GABA Transmission in Healthy Subjects and Schizophrenia Patients
Frankle, W. G., Cho, R. Y., Prasad, K. M., Mason, N. S., Paris, J., Himes, M. L., Walker, C., Lewis, D. A., & Narendran, R. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14081031 · Cited by 111
Benzodiazepines, Methadone and Buprenorphine: Interactions and Clinical Management
Lintzeris, N., & Nielsen, S. (2010) · The American Journal on Addictions · doi:10.1111/j.1521-0391.2009.00007.x · Cited by 110
Nielsen, S., Dietze, P., Lee, N., Dunlop, A., & Taylor, D. (2007) · Addiction · doi:10.1111/j.1360-0443.2006.01731.x · Cited by 93
Treating Alcohol and Drug Abuse – An Evidence Based Review
Berglund, P. D. M., Thelander, S., & Jonsson, P. D. E. (2003) · Wiley eBooks · doi:10.1002/3527601465.contrib · Cited by 89
Mura, T., Proust‐Lima, C., Akbaraly, T. N., Amieva, H., Tzourio, C., Chevassus, H., Picot, M., Jacqmin‐Gadda, H., & Berr, C. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.05.004 · Cited by 82
Sirdifield, C., Chipchase, S. Y., Owen, S., & Siriwardena, A. N. (2017) · The Patient - Patient-Centered Outcomes Research · doi:10.1007/s40271-016-0182-z · Cited by 81
Takeshima, N., Ogawa, Y., Hayasaka, Y., & Furukawa, T. A. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.01.040 · Cited by 70
Kompendium der Psychiatrischen Pharmakotherapie
Benkert, O., & Hippius, H. (2012) · Springer eBooks · doi:10.1007/978-3-642-29810-3 · Cited by 70
Pharmacological strategies for detoxification
Diaper, A., Law, F. D., & Melichar, J. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12245 · Cited by 68
Withdrawing Benzodiazepines in Patients With Anxiety Disorders
Lader, M., & Kyriacou, A. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-015-0642-5 · Cited by 67
Agonist substitution—a treatment alternative for high‐dose benzodiazepine‐dependent patients?
Liebrenz, M., Boesch, L., Stohler, R., & Caflisch, C. (2010) · Addiction · doi:10.1111/j.1360-0443.2010.02933.x · Cited by 65
Why are benzodiazepines not yet controlled substances?
Moore, N., Pariente, A., & Bégaud, B. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2190 · Cited by 62
Backmund, M., Meyer, K., Meyer, K., Soyka, M., Reimer, J., & Schütz, C. G. (2006) · Journal of Addictive Diseases · doi:10.1300/j069v24n04_02 · Cited by 58
Self-citationHypnotika – Stand der Forschung
Nissen, C., Frase, L., Hajak, G., & Wetter, T. C. (2013) · Der Nervenarzt · doi:10.1007/s00115-013-3893-6 · Cited by 53
Koyama, A., Steinman, M., Ensrud, K., Hillier, T. A., & Yaffe, K. (2013) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12093 · Cited by 52
Ten Wolde, G. B., Dijkstra, A., Van Empelen, P., Van Den Hout, W., Knuistingh Neven, A., & Zitman, F. (2008) · Addiction · doi:10.1111/j.1360-0443.2008.02141.x · Cited by 52
Baandrup, L., Glenthoj, B. Y., & Jennum, P. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.04.031 · Cited by 48
Discontinuation of Long-Term Benzodiazepine Use: 10-Year Follow-Up
de Gier, N., Gorgels, W., Lucassen, P., Oude Voshaar, R., Mulder, J., & Zitman, F. (2011) · Family Practice · doi:10.1093/fampra/cmq113 · Cited by 43
Brief intervention in general hospital for problematic prescription drug use: 12-Month outcome
Otto, C., Crackau, B., Löhrmann, I., Zahradnik, A. G., Bischof, G., John, U., & Rumpf, H. (2009) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2009.07.010 · Cited by 40
Long-term outcome of two forms of randomised benzodiazepine discontinuation
Voshaar, R. C. O., Gorgels, W. J. M. J., Mol, A. J. J., Van Balkom, A. J. L. M., Mulder, J., Van De Lisdonk, E. H., Breteler, M. H. M., & Zitman, F. G. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.bp.105.012039 · Cited by 38
Faccini, M., Leone, R., Opri, S., Casari, R., Resentera, C., Morbioli, L., Conforti, A., & Lugoboni, F. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116647505 · Cited by 38
Wo verstecken sich 1,9 Millionen Medikamentenabhängige?
Soyka, M., Queri, S., Küfner, H., & Rösner, S. (2004) · Der Nervenarzt · doi:10.1007/s00115-004-1828-y · Cited by 37
Self-citationBaandrup, L., Fagerlund, B., Jennum, P., Lublin, H., Hansen, J. L., Winkel, P., Gluud, C. N., Oranje, B., & Glenthoj, B. Y. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-160 · Cited by 35
Okumura, Y., Shimizu, S., & Matsumoto, T. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.11.010 · Cited by 32
Dependence on Prescription Benzodiazepines and Z-drugs Among Young to Middle-aged Patients in France
Guerlais, M., Grall-Bronnec, M., Feuillet, F., Gérardin, M., Jolliet, P., & Victorri-Vigneau, C. (2015) · Substance Use & Misuse · doi:10.3109/10826084.2014.980952 · Cited by 29
Mariani, J. J., Malcolm, R. J., Mamczur, A. K., Choi, J. C., Brady, R., Nunes, E., & Levin, F. R. (2016) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2015.1125493 · Cited by 27
Lohse, M. J., & Müller-Oerlinghausen, B. (2008) · Springer eBooks · doi:10.1007/978-3-540-69219-5_28 · Cited by 11
[Withdrawal phenomena in stepwise withdrawal of benzodiazepines].
Soyka, M., Steinberg, R., & Vollmer, M. (1988) · PubMed · Cited by 11
Self-citationLohse, M. J., & Müller-Oerlinghausen, B. (2013) · Springer eBooks · doi:10.1007/978-3-642-37124-0_28 · Cited by 5
Benzodiazepinabhängigkeit (ICD-10 F.13.2)
Soyka, M., & Batra, A. (2013) · Elsevier eBooks · doi:10.1016/b978-3-437-24905-1.00004-6 · Cited by 3
Self-citation
Research works printed but not linked: 7
- Amato L, 2010, Cochrane Database Syst Rev, CD005063
- Berryman SN, 2012, Medsurg Nurs, 21, 129
- Ashton H. Benzodiazepine abuse. In: Caan W, de Belleroche J, eds. Drink, drugs and dependence: from science to clinical practice. London: Routledge, 2002:197-212.
- Soyka M, 1988, Nervenarzt, 59, 744
- Darker CD, 2015, Cochrane Database Syst Rev, 5, CD009652
- Hunt GE, 2013, Cochrane Database Syst Rev, 10, CD001088
- Baillie AL, Sannibale C. Anxiety and drug and alcohol problems. In: Baker A, Velleman R, eds. Mental health and drug and alcohol problems. London: Routledge, 2007:197-217.
Cited by
Delirium Tremens: Assessment and Management
Grover, S., & Ghosh, A. (2018) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2018.04.012 · Cited by 416
“Withdrawal from benzodiazepines has a lot of common features (of alcohol withdrawal) like tremor, agitation, perceptual disturbances, seizure, and even delirium.(39) Moreover, it might also influence the dose of benzodiazepine to be used for the treatment of DT.”
BackgroundThe Diagnosis and Treatment of Anxiety Disorders
Ströhle, A., Gensichen, J., & Domschke, K. (2018) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2018.0611 · Cited by 186
Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations
Lähteenvuo, M., & Tiihonen, J. (2021) · Drugs · doi:10.1007/s40265-021-01556-4 · Cited by 217
Inpatient Addiction Consult Service
Weinstein, Z. M., Wakeman, S. E., & Nolan, S. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.03.001 · Cited by 122
Fluyau, D., Revadigar, N., & Manobianco, B. E. (2018) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125317753340 · Cited by 109
Metadata
- Authors
- Soyka, M.
- Affiliations
- Privatklinik Meiringen (CH)
- Corresponding author
- Soyka, Michael
- ORCID
- Soyka, Michael
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-03-23
- Volume
- 376
- Issue
- 12
- Pages
- 1147-1157
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2598429061
- Semantic Scholar
- 44418a0e25647425877c97f78d9d4c9dcd0f2c84
- Cited by
- 465
- References
- 66
- Citations by year
- 2026: 38 · 2025: 33 · 2024: 56 · 2023: 74 · 2022: 64 · 2021: 61 · 2020: 43 · 2019: 60 · 2018: 29 · 2017: 6
- FWCI
- 5.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- benzodiazepine dependence, benzodiazepine withdrawal, diazepam, gradual dose reduction, withdrawal symptoms, seizures, sleep disorders, anxiety
- MeSH terms
- Benzodiazepines, Diagnosis, Differential, Diazepam, Humans, Hypnotics and Sedatives, Psychotherapy, Receptors, GABA-A, Substance Withdrawal Syndrome, Anti-Anxiety Agents, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.